There is no need for a booster dose of the Kovid-19 vaccine for the general population of the world. Two prominent officials of the US Food and Drug Administration and several prominent scientists of the World Health Organization (WHO) have said this in an article published in a medical journal. Scientists said that more evidence is needed to justify the use of booster doses. This is in contrast to the US government’s plan to give a third dose to fully vaccinated people from next week.
Actually, the US government plans to apply booster doses to fully vaccinated American citizens. However, approval from health regulators is yet to be taken for this. The cases of Kovid-19 are increasing due to the delta variant of Coronavirus. In such a situation, the administration of President Joe Biden is concerned that people who have been vaccinated are now getting infected. This shows that the protection of vaccinated people is decreasing over time. Because of this, the administration is emphasizing on booster doses to prepare immunity.
This was said about booster dose
The WHO has argued that the vaccine is still needed for the first dose worldwide. The scientists wrote in the Lancet medical journal, any decision regarding booster dose and timing of booster dose should be based on adequate clinical and epidemiological data, or both. These data should show that due to them there is a decline in serious diseases. He said, the risk-benefit assessment should be based on how many Kovid cases are reduced due to the booster dose. Also, is the booster dose safe and effective against the current variant?
Booster dose is being imposed in many countries
The scientists wrote, “Current evidence shows that the general population does not need a booster dose, as the vaccine is effective against serious disease.” Some countries have started Kovid-19 booster campaign. This includes Israel as well. These countries have provided some data, keeping in mind that the Biden administration has planned to introduce additional booster doses. The authors of this article include Marion Gruber, director of the FDA’s Office of Vaccine Research and Review, and Phil Krause, deputy director. Both men are due to leave the FDA in the coming months. They say that some people want to make profit through this.